Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.

Jung-Min Lee Richard G Moore Sharad A Ghamande Min S Park John P Diaz Julia Chapman James Kendrick Brian M Slomovitz Krishnansu S Tewari Elizabeth S Lowe Tsveta Milenkova Sanjeev Kumar Mike Dymond Jessica Brown Joyce F Liu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Clinical activity was shown for the cedi/ola combination in heavily pretreated, non-gBRCAm, platinum-resistant patients with ovarian cancer despite failing to meet the target ORR of 20%, highlighting a need for further biomarker studies.

Keyphrases

end stage renal disease
newly diagnosed
clinical trial
study protocol
phase iii
oxidative stress